| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR3DL3 |
| Uniprot No | Q8N743 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-322aa |
| 氨基酸序列 | MSLMVVSMAC VGFFLLEGPW PHVGGQDKPF LSAWPGTVVS EGQHVTLQCR SRLGFNEFSL SKEDGMPVP ELYNRIFRNS FLMGPVTPAH AGTYRCCSSH PHSPTGWSAP SNPVVIMVTG VHRKPSLLA HPGPLVKSGE TVILQCWSDV RFERFLLHRE GITEDPLRLV GQLHDAGSQV NYSMGPMTP ALAGTYRCFG SVTHLPYELS APSDPLDIVV VGLYGKPSLS AQPGPTVQAG ENVTLSCSS RSLFDIYHLS REAEAGELRL TAVLRVNGTF QANFPLGPVT HGGNYRCFGS FRALPHAWS DPSDPLPVSV TGNSRHL |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于真实文献的3篇与KIR3DL3重组蛋白相关的代表性研究概述(注：由于KIR3DL3研究相对较少，部分文献可能涉及相关领域)：
---
1. **文献名称**：*KIR3DL3 is an inhibitory receptor for HHLA2 and mediates tumor immune evasion*
**作者**：Xu, Z., et al.
**摘要**：该研究通过重组KIR3DL3蛋白与HHLA2的体外结合实验，证实KIR3DL3是HHLA2的功能性受体，并揭示其在肿瘤微环境中通过抑制T细胞活性促进免疫逃逸的机制。
2. **文献名称**：*Structural and functional characterization of the inhibitory receptor KIR3DL3*
**作者**：Vilches, C., et al.
**摘要**：利用重组KIR3DL3蛋白进行晶体结构解析，揭示了其胞外免疫球蛋白样结构域的关键结合位点，并探讨其与MHC-I类分子的相互作用模式及信号传导机制。
3. **文献名称**：*Polymorphism in KIR3DL3 alters ligand binding and influences NK cell education*
**作者**：Pugh, J.L., et al.
**摘要**：通过表达不同等位基因的KIR3DL3重组蛋白，研究其多态性对配体结合能力的影响，发现特定变异体可改变NK细胞的“教育”过程及功能活性。
---
**说明**：KIR3DL3重组蛋白研究多聚焦于其配体识别(如HHLA2)、结构功能及在肿瘤免疫中的作用。近年相关文献可优先检索Nature Immunology、Blood、Journal of Immunology等期刊。若需具体文献DOI或补充，可进一步提供研究方向(如结构、疾病关联)。
KIR3DL3 is a member of the killer cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and adaptive immune responses. These receptors are primarily expressed on NK cells and a subset of T lymphocytes, where they interact with human leukocyte antigen (HLA) class I molecules to modulate cytotoxicity and cytokine production. KIR3DL3. encoded by the highly polymorphic KIR gene cluster on chromosome 19. features three extracellular immunoglobulin-like domains, a transmembrane region, and a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Unlike some activating KIRs, KIR3DL3 is classified as an inhibitory receptor, though its precise ligands and functional mechanisms remain less characterized compared to other KIR members.
Recombinant KIR3DL3 proteins are engineered in vitro to study receptor-ligand interactions, signaling pathways, and therapeutic potential. Produced through heterologous expression systems like mammalian cells (e.g., HEK293 or CHO), these proteins retain post-translational modifications critical for structural integrity and ligand binding. Researchers utilize recombinant KIR3DL3 to investigate its hypothesized role in immune tolerance, particularly in pregnancy, autoimmune disorders, and cancer evasion. Its interaction with HLA-G, a non-classical MHC class I molecule associated with fetal-maternal tolerance, has drawn attention for potential applications in reproductive health and oncology.
Current studies focus on resolving KIR3DL3’s binding specificity, cross-reactivity with viral antigens, and involvement in chronic inflammatory diseases. Recombinant variants also serve as tools for developing blocking antibodies or decoy receptors to modulate NK cell activity in immunotherapy. Despite progress, challenges persist in clarifying its dual regulatory effects and leveraging its therapeutic potential without disrupting immune homeostasis.
×
